CANbridge to Present CAN106 Phase 1 Data at the European Hematology Association 2022 Congress

BEIJING & CAMBRIDGE, Mass.–(BUSINESS WIRE)–CANbridge Pharmaceuticals, Inc. (HKEX:1228), a China-based global biopharmaceutical company committed to the research, development and commercialization of transformative rare disease and rare oncology therapies, announced that data from its CAN106 Phase 1 trial will be presented at the 2022 European Hematology Association Congress, in Vienna, Austria, on June 10^th.

Poster Details:

Title: A Phase 1 Single Ascending Dose Study of CAN106, a Long-Acting Anti-C5 Complement Monoclonal Antibody in Clinical Development for PNH and Other Complement-Mediated Diseases

Abstract code: P822

Time and Date: Friday, June 10, 16:30 – 17:45 CEST

Authors: Chin Meng Khoo¹, Charlene Song², Qizhen Wu², Gerry Cox²

Affiliations:

1. Department of Medicine, National University Hospital, Singapore

2. Clinical Development and Medical Affairs, CANbridge Pharmaceuticals.

Abstracts are available on the EHA website: https://ehaweb.org/congress/eha2022-hybrid/eha2022-congress/.

About CANbridge Pharmaceuticals Inc.

CANbridge Pharmaceuticals Inc. (HKEX:1228) is a China-based global biopharmaceutical company committed to the research, development and commercialization of transformative therapies for rare disease and rare oncology. CANbridge has a differentiated drug portfolio, with three approved drugs and a pipeline of 11 assets, targeting prevalent rare disease and rare oncology indications that have unmet needs and significant market potential. These include Hunter syndrome and other lysosomal storage disorders, complement-mediated disorders, hemophilia A, metabolic disorders, rare cholestatic liver diseases and neuromuscular diseases, as well as glioblastoma multiforme. CANbridge is also building next-generation gene therapy development capability through a combination of collaboration with world-leading researchers and biotech companies and internal capacity. CANbridge global partners include: Apogenix, GC Pharma, Mirum, Wuxi Biologics, Privus, the UMass Chan Medical School and LogicBio.

For more on CANbridge Pharmaceuticals Inc., please go to: www.canbridgepharma.com.

Forward-Looking Statements

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the data on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development.

Contacts

Investor Relations:
US
Chris Brinzey
ICR Westwicke
[email protected]

China
CANbridge Pharmaceuticals Inc.
[email protected]

Media:
Deanne Eagle
Planet Communications
[email protected]
917.837.5866